News

Palatin reports positive Phase 2 appetite suppression results
Palatin (PTN) announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered ...
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...